Charles Darwin University

CDU eSpace
Institutional Repository

CDU Staff and Student only

Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults (Review)

Chang, Anne B., Lasserson, Toby J., Gaffney, Justin, Connor, Frances L. and Garske, Luke A. (2011). Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults (Review). Cochrane Database of Systematic Reviews,2011(1):1-64.

Document type: Journal Article
Attached Files (Some files may be inaccessible until you login with your CDU eSpace credentials)
Name Description MIMEType Size Downloads
Download this reading Chang_37939.pdf Published version application/pdf 773.30KB 390
Reading the attached file works best in Firefox, Chrome and IE 9 or later.

IRMA ID jsingletonxPUB27
NHMRC Grant No. 545216
Title Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults (Review)
Author Chang, Anne B.
Lasserson, Toby J.
Gaffney, Justin
Connor, Frances L.
Garske, Luke A.
Journal Name Cochrane Database of Systematic Reviews
Publication Date 2011
Volume Number 2011
Issue Number 1
ISSN 1469-493X   (check CDU catalogue open catalogue search in new window)
Start Page 1
End Page 64
Total Pages 64
Place of Publication United Kingdom
Publisher John Wiley & Sons Ltd.
HERDC Category C1 - Journal Article (DIISR)
Abstract Background
Gastroesophageal reflux disease (GORD) is said to be the causative factor in up to 41% of adults with chronic cough. Treatment for GORD includes conservative measures (diet manipulation), pharmaceutical therapy (motility or prokinetic agents, H2-antagonist and proton pump inhibitors (PPI)) and fundoplication.

To evaluate the efficacy of GORD treatment on chronic cough in children and adults with GORD and prolonged cough that is not related to an underlying respiratory disease, i.e. non-specific chronic cough.

Search methods
We searched the Cochrane Airways Group Specialised Register, the Cochrane Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, review articles and reference lists of relevant articles. The date of last search was 8 April 2010.

Selection criteria
All randomised controlled trials (RCTs) on GORD treatment for cough in children and adults without primary lung disease.

Data collection and analysis
Two review authors independently assessed trial quality and extracted data. We contacted study authors for further information.

Main results
We included 19 studies (six paediatric, 13 adults). None of the paediatric studies could be combined for meta-analysis. A single RCT in infants found that PPI (compared to placebo) was not efficacious for cough outcomes (favouring placebo OR 1.61; 95% CI 0.57 to 4.55) but those on PPI had significantly increased adverse events (OR 5.56; 95% CI 1.18 to 26.25) (number needed to treat for harm in four weeks was 11 (95% CI 3 to 232)). In adults, analysis of H2 antagonist, motility agents and conservative treatment for GORD was not possible (lack of data) and there were no controlled studies of fundoplication. We analysed nine adult studies comparing PPI (two to three months) to placebo for various outcomes in the meta-analysis. Using intention-to-treat, pooled data from studies resulted in no significant difference between treatment and placebo in total resolution of cough (OR 0.46; 95% CI 0.19 to 1.15). Pooled data revealed no overall significant improvement in cough outcomes (end of trial or change in cough scores). We only found significant differences in sensitivity analyses. We found a significant improvement in change of cough scores at end of intervention (two to three months) in those receiving PPI (standardised mean difference -0.41; 95% CI -0.75 to -0.07) using generic inverse variance analysis on cross-over trials. Two studies reported improvement in cough after five days to two weeks of treatment.

Authors' conclusions
PPI is not efficacious for cough associated with GORD symptoms in very young children (including infants) and should not be used for cough outcomes. There is insufficient data in older children to draw any valid conclusions. In adults, there is insufficient evidence to conclude definitely that GORD treatment with PPI is universally beneficial for cough associated with GORD. Clinicians should be cognisant of the period (natural resolution with time) and placebo effect in studies that utilise cough as an outcome measure. Future paediatric and adult studies should be double-blind, randomised controlled and parallel-design, using treatments for at least two months, with validated subjective and objective cough outcomes and include ascertainment of time to respond as well as assessment of acid and/or non-acid reflux.
DOI   (check subscription with CDU E-Gateway service for CDU Staff and Students  check subscription with CDU E-Gateway in new window)

© copyright

Every reasonable effort has been made to ensure that permission has been obtained for items included in CDU eSpace. If you believe that your rights have been infringed by this repository, please contact

Version Filter Type
Access Statistics: 115 Abstract Views, 390 File Downloads  -  Detailed Statistics
Created: Fri, 17 Jan 2014, 01:02:47 CST